Does treatment with less than 50% of recommended dose of ACE-inhibitors/ARBs and beta-blockers increase the risk of death and/or heart failure hospitalization compared to reaching ≥100% in patients with HFrEF?
Suboptimal dosing (<50% of recommended) of ACE-inhibitors/ARBs and beta-blockers in HFrEF is associated with worse clinical outcomes compared to achieving target doses.
Patients with HFrEF who were treated with less than 50% of recommended dose of ACE-inhibitors/ARBs and beta-blockers seemed to have a greater risk of death and/or heart failure hospitalization compared with patients reaching ≥100%.
Ouwerkerk et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: